

CSbioactive[®]

The benchmark Chondroitin sulfate



Bioiberica's **CSbioactive[®]** is a widely researched chondroitin sulfate shown to induce an anabolic and anti-catabolic response in the cartilage of animals, supporting joint health. A complex biological substance,

CSbioactive[®] stands out for its unique molecular properties (100% purity), ensuring a highly purified, intact, and consistent molecule manufactured to the highest quality standards.

CS-Bioactive[®] has demonstrated its effects in more than 40 preclinical, clinical and epidemiological studies.

RECOMMENDED CLAIMS

- Increased in vitro synthesis of the cartilage matrix components.
- In vitro and in vivo evidence of cartilage preservation.
- Helps to maintain joint health.

PRODUCT DOSE in pet food

The combined administration of CSbioactive and Glucosamine is recommended to optimize the results.

High dosage

1.000-2.000 ppm CSbioactive
1000 ppm Glucosamine


Medium dosage

350 ppm CSbioactive
1450 ppm Glucosamine

Low dosage

225 ppm CSbioactive
275 ppm Glucosamine





CSbioactive®



TRIAL

Segarra S, et al. Effects of orally administered chondroitin sulfate on joint functional impairment in senior dogs affected by osteoarthritis. BSAVA Congress 2013, Birmingham, UK.

The objective of this prospective, double-blind, randomized, multicenter study to compare the severity of joint dysfunction in senior dogs before and after treatment with Chondroitin sulfate CSbioactive. A total of 44 dogs with osteoarthritis were included in the study, with an average age

of 9.9 years and were randomly separated into 2 groups: placebo and Chondroitin sulfate, for 60 days. A physical, functional and activity level examination was performed on days 0, 20, 40, 60 and 20 days after the end of the treatment. The level of activity improved in the Chondroitin sulfate group, and in the functional assessment, this improvement was 29.4% in this group while it was 0% in the placebo group. The pain degree was significantly reduced ($p < 0,05$) at 60 and 80 days in the chondroitin group.

RESULTS

The results show that the administration of Chondroitin sulfate improves functional limitation and the degree of pain in senior dogs with osteoarthritis, implying a substantial improvement in their quality of life. In addition, a carry-over effect of the product was observed after discontinuing its use at 60 days, and no side effects were seen in the two treatment groups.

TRIAL

Velasco A, et al. Evaluation of the clinical efficacy of Chondroitin sulfate in dogs with knee osteoarthritis secondary to rupture of the anterior cruciate ligament, after replacement surgery Revista AVEPA Vol. 29, n°2, 2009.

Comparative study in 41 dogs with osteoarthritis suffering anterior cruciate ligament injury surgery, treated with

Chondroitin sulfate CSbioactive vs. placebo for 120 days. Mobility, clinical signs and osteoarthritis severity were more favorable in the Chondroitin sulfate group, suggesting a positive impact on disease symptoms.

RESULTS

The results of this study suggest that oral administration of Chondroitin sulfate after anterior cruciate ligament replacement intervention contributes in the short-medium term to the recovery of joint mobility and to mitigate osteoarthritis severity and symptoms.